Sofosbuvir/Velpatasvir
Treatment for Acute Hepatitis C
Typical Dosage: 400 mg sofosbuvir / 100 mg velpatasvir once daily
Effectiveness
98%
Safety Score
70%
Clinical Trials
1
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
400 mg sofosbuvir / 100 mg velpatasvir once daily
Time to Effect
Within 12 weeks of treatment completion
Treatment Duration
8-12 weeks
Evidence Quality
HIGHNumber Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$25,000
Monitoring:$1,000
Side Effect Mgmt:$200
Total Annual:$26,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$50,000/QALY
QALYs Gained
3
Outcome-Based Costs
Cost per Responder
$26,735
Cost per Remission
$26,735
Comparison vs Pegylated Interferon + Ribavirin
Cost Difference
$-8,800/year
Less expensive
QALY Difference
+2.50 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Prescription Access Economics
Annual Societal Loss per Patient
$20,390
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$20/year
Prior auth, claims
Rx Price
$25,000/year
Potential OTC Price
$5,000/year
Estimated if OTC available
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWSofosbuvir/Velpatasvir Outcomes
for Acute Hepatitis C
Efficacy Outcomes
Overall Effectiveness
+98%
Response Rate
+98%
Remission Rate
+98%
Common Side Effects
Headache
+21%
Fatigue
+18%
Nausea
+11%
Diarrhea
+6%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Sofosbuvir/Velpatasvir in Acute Hepatitis C
Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
NCT03818308COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Berlin, Germany +13 more
Started: May 28, 2019